RxDoctor Payments Data

Wesley Payne, MD

Family Medicine · Seymour, TNNPI 1053415455

Payments from drug & device makers

$13,108in general payments, 2019–2025

Across 846 payments — averaging $15.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • GSK$1K
  • Pfizer$909
  • E.r. Squibb & Sons, L.L.C.$724
  • Lilly USA, LLC$704
  • plus $6K from 41 others

What the payments were for

  • Food & beverage$13,096100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,108 in reported general payments places this provider in the 95th percentile of 2,087 family medicine providers in Tennessee.

See all family medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$142,210
Medicare patients
281
Services billed
4,903

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban126$127,245
JardianceEmpagliflozin74$62,379
OzempicSemaglutide29$45,599
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$44,472
ShingrixVaricella-Zoster Ge/As01b/Pf177$40,288
XareltoRivaroxaban42$33,878
FarxigaDapagliflozin Propanediol41$30,339
ArexvyRsvpref3 Antigen/As01e/Pf88$28,630
JanuviaSitagliptin Phosphate17$18,229
TradjentaLinagliptin19$16,752
MounjaroTirzepatide16$16,130
Breo ElliptaFluticasone/Vilanterol26$13,264
Lantus SolostarInsulin Glargine,hum.Rec.Anlog68$11,061
MyrbetriqMirabegron15$7,659
SymbicortBudesonide/Formoterol Fumarate18$7,567

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$909$127,245126 claims
GSKTrelegy Ellipta, Shingrix, Arexvy, Breo Ellipta$1,029$126,654338 claims
Boehringer IngelheimJardiance, Tradjenta$604$79,13193 claims
Novo NordiskOzempic, Novolog Mix 70-30$1,907$48,99543 claims
AstraZenecaFarxiga, Symbicort$517$37,90659 claims
Johnson & JohnsonXarelto$317$33,87842 claims
MerckJanuvia$326$18,22917 claims
Lilly USA, LLCMounjaro$704$16,13016 claims
Astellas Pharma US IncMyrbetriq$220$7,65915 claims
Sanofi-aventis U.S. LLCLantus$167$4,76611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,087 family medicine providers in Tennessee.

Other family medicine in Seymour

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →